Valneva SE confirmed earnings guidance for the fiscal year 2024. For the period, expected total revenues between ?170 million and ?190 million, including: 160 million to ?180 million of sales driven by growth of Valneva?s proprietary products.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.436 EUR | +2.44% |
|
+7.31% | -27.20% |
Jul. 01 | Valneva's Secures Marketing Authorization in Europe for Chikungunya Vaccine | MT |
Jul. 01 | New semester, new state of mind | ![]() |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.20% | 521M | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- VLA Stock
- News Valneva
- Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024